NISHITH.TV
  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York

Locations

  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • Munich
  • New York
  • Content
  • Home
  • ABOUT US
  • NDA in the Media
  • Areas of Service
  • Research and Articles
  • Opportunities
  • Contact
  • NDACloud
  • Client Access
  • Member Access
  • Events and Calender
  • How we perform
  • Knowledge anywhere, anytime
  • See our recent deals
  • Up to date legal developments
  • Case studies in M&A

Research and Articles

HTMLPDF

  • Research at NDA
  • Research Papers
  • Research Articles
  • NDA Think Tanks
  • NDA Hotline
  • New Ali Gunjan
  • Japan Desk ジャパンデスク

NDA-Hotline


  • Debt Funding in India Series
  • Private Equity Corner
  • The Startups Series
  • Court Corner
  • Investment Funds: Monthly Digest
  • Insolvency and Bankruptcy Hotline
  • Deal Destination
  • New Publication
  • M&A Interactive
  • Lit Corner
  • Private Debt Hotline
  • Food & Beverages Hotline
  • Companies Act Series
  • Gaming Law Wrap
  • Private Client Wrap
  • GIFT City Express
  • Regulatory Hotline
  • Capital Markets Hotline
  • Tax Hotline
  • Corpsec Hotline
  • Dispute Resolution Hotline
  • M&A Hotline
  • Pharma & Healthcare Update
  • Competition Law Hotline
  • HR Law Hotline
  • IP Hotline
  • Telecom Hotline
  • FEMA Hotline
  • Social Sector Hotline
  • iCe Hotline
  • SEZ Hotline
  • Media Hotline
  • Funds Hotline
  • Education Sector Hotline
  • International Trade Hotlines
  • Other Hotline
  • Real Estate Update
  • Realty Check
  • White Collar and Investigations Practice
  • Legal Update
  • IP Lab
  • Cross Examination
  • Technology & Tax Series
  • Technology Law Analysis
  • Yes, Governance Matters.
  • Financial Service Update
  • Japan Desk ジャパンデスク

IP Lab

March 21, 2012

Pharma Patent Case Study

Dear All,

On 9th March, 2012, the Controller General of Patents Design and Trademarks of India, Mr. P.H. Kurian, marked his last day in office with a landmark judgment granting the first ever compulsory license to an Indian generic pharmaceutical company Natco Pharma to manufacture and sell a generic version of Bayer Corporation's patent protected anti-cancer drug 'Sorafenib Tosyalte' (NEXAVAR).

This watershed development is likely to alter the complexion of the pharmaceutical industry in India. This judgment brings to the fore many contentious issues such as whether "local manufacturing" of a patented invention is mandatory in India, what drug price is "reasonable" under the current patent regime .


Please click here for the document analyzing this path breaking judgment with our views and insights



- Aditi Jha, Gowree Gokhale & Dr. Milind Antani
You can direct your queries or comments to IP-Pharma Team

Mission and Vision


Distinctly Different

What's New


Not-for-profits Rejoice: Receiving Foreign Contributions Made Easy
Social Sector Hotline: July 06,2022
Supreme Court’s quick fix for backlog in arbitral appointments by High Courts
Dispute Resolution Hotline : July 06,2022

Events


Webinars

Sustainable Mobility: Opportunities and Challenges
June 09,2022 - June 09,2022

This event is over. For event material please click here


Seminar

Navigating Disputes in India
February 26,2020 - February 26,2020

This event is over. For event material please click here


Round Table

Investing In Net Zero
July 14,2022 - July 14,2022

News Roundup


News Articles

Impact of Supreme Court’s new covidvaccination ruling on India’s employers
May 13,2022

Quotes

Nod for 80 FDI proposals from China entities
July 06,2022

Newsletters


Social Sector Hotline

Not-for-profits Rejoice: Receiving Foreign Contributions Made Easy
July 06,2022

Dispute Resolution Hotline

Supreme Court’s quick fix for backlog in arbitral appointments by High Courts
July 06,2022

Debt Funding in India Series

Credit Default Swap: Grooming the Infamous Device
July 05,2022

  • Disclaimer
  • Content
  • Feedback
  • Walkthrough
  • Subscribe
Nishith Desai Associates@2016 All rights reserved.